Array BioPharma Inc. and VentiRx Pharmaceuticals Inc. have announced that the two companies have entered into a license agreement granting VentiRx exclusive worldwide rights to Array’s Toll-like ...

After Array BioPharma (NASDAQ: ARRY) announced quarterly results and shared some clinical news with investors on Tuesday, shares of the cancer-focused clinical-stage biotech jumped and were up 18% as ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...

Array BioPharma (ARRY) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.11 per share a year ago. These figures are ...

BOULDER, Colo. (AP) _ Array BioPharma Inc. (ARRY) on Wednesday reported a loss of $35.3 million in its fiscal third quarter. The Boulder, Colorado-based company said it had a loss of 21 cents per ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Array BioPharma Inc. ARRY was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...

What: Shares of Array Biopharma opened 10% higher this morning but have since settled into a modest 2% gain as investors digest the small biotech's latest earnings report. The stock has had difficulty ...